Discovery and development of anticancer aptamers

被引:394
|
作者
Ireson, Christopher R. [1 ]
Kelland, Lloyd R. [1 ]
机构
[1] Antisoma Res Labs, London, England
关键词
D O I
10.1158/1535-7163.MCT-06-0172
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aptamers, also termed as decoys or "chemical antibodies," represent an emerging class of therapeutics. They are short DNA or RNA oligonucleotides or peptides that assume a specific and stable three-dimensional shape in vivo, thereby providing specific tight binding to protein targets. In some cases and as opposed to antisense oligonucleotides, effects can be mediated against extracellular targets, thereby preventing a need for intracellular transportation. The first aptamer approved for use in man is a RNA-based molecule (Macugen, pegaptanib) that is administered locally (intravitreally) to treat age-related macular degeneration by targeting vascular endothelial growth factor. The most advanced aptamer in the cancer setting is AS 1411, formerly known as AGRO 100, which is being administered systemically in clinical trials. AS1411 is a 26-mer unmodified guanosine-rich oligonucleotide, which induces growth inhibition in vitro, and has shown activity against human tumor xenografts in vivo. The mechanism underlying its antiproliferative effects in cancer cells seems to involve initial binding to cell surface nucleolin and internalization, leading to an inhibition of DNA replication. In contrast to other unmodified oligonucleotides, AS 1411 is relatively stable in serum-containing medium, probably as a result of the formation of dimers and a quartet structure. In a dose escalation phase I study in patients with advanced solid tumors, doses up to 10 mg/kg/d (using a four or seven continuous infusion regime) have been studied. Promising signs of activity have been reported (multiple cases of stable disease and one near complete response in a patient with renal cancer) in the absence of any significant adverse effects. Further trials are ongoing in renal and non-small cell lung cancers. In preclinical studies, additional aptamers have been described against several cancer targets, such as tenascin-C, the transcription factor signal transducer and activator of transcription 3, and antiapoptotic and Ku proteins.
引用
收藏
页码:2957 / 2962
页数:6
相关论文
共 50 条
  • [31] CNS Anticancer Drug Discovery and Development Conference White Paper
    Levin, Victor A.
    Tonge, Peter J.
    Gallo, James M.
    Birtwistle, Marc R.
    Dar, Arvin C.
    Iavarone, Antonio
    Paddison, Patrick J.
    Heffron, Timothy P.
    Elmquist, William F.
    Lachowicz, Jean E.
    Johnson, Ted W.
    White, Forest M.
    Sul, Joohee
    Smith, Quentin R.
    Shen, Wang
    Sarkaria, Jann N.
    Samala, Ramakrishna
    Wen, Patrick Y.
    Berry, Donald A.
    Petter, Russell C.
    NEURO-ONCOLOGY, 2015, 17 : 1 - 26
  • [32] Progress in the discovery and development of anticancer agents from marine cyanobacteria
    Luesch, Hendrik
    Ellis, Emma K.
    Chen, Qi-Yin
    Ratnayake, Ranjala
    NATURAL PRODUCT REPORTS, 2025, 42 (02)
  • [33] Discovery and Development of Promising Anticancer Agents via Computational and Experimental
    Carradori, Simone
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2024, 24 (04) : 235 - 235
  • [34] Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: A new anticancer drug
    McMorris, TC
    BIOORGANIC & MEDICINAL CHEMISTRY, 1999, 7 (05) : 881 - 886
  • [35] Promise and challenges in drug discovery and development of hybrid anticancer drugs
    Gediya, Lalji K.
    Njar, Vincent C. O.
    EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (11) : 1099 - 1111
  • [36] The role of mouse tumour models in the discovery and development of anticancer drugs
    Christopher R. Ireson
    Mo S. Alavijeh
    Alan M. Palmer
    Emily R. Fowler
    Hazel J. Jones
    British Journal of Cancer, 2019, 121 : 101 - 108
  • [37] Genomic SELEX: A discovery tool for genomic aptamers
    Zimmermann, Bob
    Bilusic, Ivana
    Lorenz, Christina
    Schroeder, Renee
    METHODS, 2010, 52 (02) : 125 - 132
  • [38] Aptamers generated by Cell SELEX for biomarker discovery
    Kim, Youngmi
    Liu, Chen
    Tan, Weihong
    BIOMARKERS IN MEDICINE, 2009, 3 (02) : 193 - 202
  • [39] Disease-Specific Biomarker Discovery by Aptamers
    Ulrich, Henning
    Wrenger, Carsten
    CYTOMETRY PART A, 2009, 75A (09) : 727 - 733
  • [40] Cancer biomarker discovery using DNA aptamers
    Jin, Cheng
    Qiu, Liping
    Li, Jin
    Fu, Ting
    Zhang, Xiaobing
    Tan, Weihong
    ANALYST, 2016, 141 (02) : 461 - 466